Vectus Biosystems Limited (ASX:VBS)
0.1300
0.00 (0.00%)
Mar 4, 2026, 9:59 AM AEST
Vectus Biosystems Revenue
Vectus Biosystems had revenue of 84.48K AUD in the half year ending June 30, 2025, a decrease of -89.10%. This brings the company's revenue in the last twelve months to 89.96K, down -89.83% year-over-year. In the fiscal year ending June 30, 2025, Vectus Biosystems had annual revenue of 478.18K, down -58.01%.
Revenue (ttm)
89.96K
Revenue Growth
-89.83%
P/S Ratio
77.21
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 478.18K | -660.49K | -58.01% |
| Jun 30, 2024 | 1.14M | -215.86K | -15.94% |
| Jun 30, 2023 | 1.35M | 54.45K | 4.19% |
| Jun 30, 2022 | 1.30M | 282.09K | 27.71% |
| Jun 30, 2021 | 1.02M | 966.81K | 1,888.82% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chimeric Therapeutics | 9.75M |
| Immuron | 7.48M |
| Tissue Repair | 3.26M |
| Acrux | 2.81M |
| Nexalis Therapeutics | 767.69K |
| Anatara Lifesciences | 623.76K |
| AdAlta | 608.07K |
| Bio-Gene Technology | 390.63K |
Vectus Biosystems News
- 27 days ago - XORTX Extends Closing Of Renal Anti-Fibrotic Therapeutic Program Acquisition; Stock Soars - Nasdaq